Rapid Molecular Diagnosis of Strep A Infections Now Available in Multiple US Healthcare Settings
By LabMedica International staff writers Posted on 10 Aug 2015 |
A molecular diagnostic platform that detects Group A Streptococcus (GAS) infections in eight minutes or less was awarded a CLIA (Clinical Laboratory Improvement Amendments) waiver by the [US] Food and Drug Administration, which paves the way for its use in a broad range of healthcare settings.
The Alere Inc. (Waltham, MA, USA) i Strep A test, which was initially approved for diagnostics use in the USA in April 2015, now joins the Alere i Influenza A & B assay as the first-ever molecular tests to receive a CLIA waiver.
Alere i Strep A detects GAS bacteria in throat swab specimens using the company's proprietary Molecular in Minutes (MIM) isothermal nucleic acid amplification technology (iNAT). Unlike polymerase chain reaction (PCR) tests, iNAT does not require lengthy and complex thermocycling or DNA purification and can therefore deliver PCR-caliber results more quickly and in a broad range of settings. Thus rapid (less than eight minutes) GAS diagnostics will be available in a broad range of healthcare settings, including physician offices, hospital emergency rooms, and retail and walk-in clinics in the USA.
“Strep A is highly transmissible, and prompt treatment is critical to reducing the spread of the infection to others. With CLIA waiver for the Alere i Strep A test, we can help link more people to early treatment by bringing rapid molecular diagnosis to even more settings where they seek health care,” said Avi Pelossof, global president of infectious disease at Alere.
Related Links:
Alere Inc.
The Alere Inc. (Waltham, MA, USA) i Strep A test, which was initially approved for diagnostics use in the USA in April 2015, now joins the Alere i Influenza A & B assay as the first-ever molecular tests to receive a CLIA waiver.
Alere i Strep A detects GAS bacteria in throat swab specimens using the company's proprietary Molecular in Minutes (MIM) isothermal nucleic acid amplification technology (iNAT). Unlike polymerase chain reaction (PCR) tests, iNAT does not require lengthy and complex thermocycling or DNA purification and can therefore deliver PCR-caliber results more quickly and in a broad range of settings. Thus rapid (less than eight minutes) GAS diagnostics will be available in a broad range of healthcare settings, including physician offices, hospital emergency rooms, and retail and walk-in clinics in the USA.
“Strep A is highly transmissible, and prompt treatment is critical to reducing the spread of the infection to others. With CLIA waiver for the Alere i Strep A test, we can help link more people to early treatment by bringing rapid molecular diagnosis to even more settings where they seek health care,” said Avi Pelossof, global president of infectious disease at Alere.
Related Links:
Alere Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia